From: Effect of congenital heart disease on the recurrence of cough variant asthma in children
Characteristic | Non-CHD | CHD | P value | ||
---|---|---|---|---|---|
N = 134 | N = 67 | ||||
N | % | N | % | ||
Clinical presentation | |||||
Age (year) | 0.99 | ||||
1–3 | 54 | 40.3 | 27 | 40.3 | |
4–6 | 38 | 28.4 | 19 | 28.4 | |
7–14 | 42 | 31.3 | 21 | 31.3 | |
Sex | 0.99 | ||||
Male | 74 | 55.2 | 37 | 55.2 | |
Female | 60 | 44.8 | 30 | 44.8 | |
Family history of allergies | 123 | 91.8 | 57 | 85.1 | 0.150 |
Family history of eczema | 64 | 47.8 | 30 | 44.8 | 0.689 |
Family history of asthma | 26 | 19.4 | 14 | 20.9 | 0.803 |
Laboratory examination | |||||
Elevated eosinophil ratio | 44 | 32.8 | 18 | 26.8 | 0.388 |
Mycoplasma pneumonia positive | 69 | 51.5 | 38 | 56.7 | 0.484 |
sIgE sensitization | 85 | 63.4 | 40 | 59.7 | 0.607 |
Food | 70 | 52.2 | 32 | 47.8 | 0.549 |
Aeroallergen | 84 | 62.7 | 37 | 55.2 | 0.308 |
Treatment | 0.99 | ||||
Fluticasone Propionate inhalation aerosol (flixotide) + salbutamol | 92 | 68.7 | 46 | 68.7 | |
Salmeterol xinafoate and fluticasone propionate powder for inhalation (seretide) + salbutamol | 42 | 31.3 | 21 | 31.3 |